Time filter

Source Type

Zhang F.-L.,Maanshan City Peoples Hospital | Gao E.-Y.,Maanshan City Peoples Hospital | Shu R.-B.,Maanshan City Peoples Hospital | Wang H.,Maanshan City Peoples Hospital | And 7 more authors.
Asian Pacific Journal of Cancer Prevention | Year: 2015

Aims: To study the effectiveness of human recombinant endostatin injection (Endostar®) combined with cisplatin doublets in treating advanced non-small cell lung cancer (NSCLC), and to evaluate outcome by CT perfusion imaging. Methods: From April 2011 to September 2014, 76 patients with advanced NSCLC who were treated with platinum-based doublets were divided into group A (36 patients) and group B (40 patients). Endostar® 15mg/day was administered 4 days before chemotherapy and combined with chemotherapy from day 5 in group A, and combined with chemotherapy from the first day in Group B. Endostar® in the two groups was injected intravenously for 14 days. Results: Treatment effectiveness in the two groups differed with statistical significance (p < 0.05). Effectiveness evaluated by CT perfusion imaging, BF, BV, MTT and PS also demonstrated significant differences (all p < 0.05). Adverse reactions in the two groups did not significantly vary (p > 0.05). Conclusions: The response rate with Endostar® administered 4 days before chemotherapy and combined with chemotherapy from day 5 in group A was better than Endostar® combined with chemotherapy from the first day, and CT perfusion imaging could be a reasonable method for evaluation of patient outcomes.


PubMed | Maanshan City Peoples Hospital
Type: Journal Article | Journal: Asian Pacific journal of cancer prevention : APJCP | Year: 2015

To study the effectiveness of human recombinant endostatin injection (Endostar) combined with cisplatin doublets in treating advanced non-small cell lung cancer (NSCLC), and to evaluate outcome by CT perfusion imaging.From April 2011 to September 2014, 76 patients with advanced NSCLC who were treated with platinum-based doublets were divided into group A (36 patients) and group B (40 patients). Endostar 15 mg/day was administered 4 days before chemotherapy and combined with chemotherapy from day 5 in group A, and combined with chemotherapy from the first day in Group B. Endostar in the two groups was injected intravenously for 14 days.Treatment effectiveness in the two groups differed with statistical significance (p<0.05). Effectiveness evaluated by CT perfusion imaging, BF, BV, MTT and PS also demonstrated significant differences (all p<0.05). Adverse reactions in the two groups did not significantly vary (p>0.05).The response rate with Endostar administered 4 days before chemotherapy and combined with chemotherapy from day 5 in group A was better than Endostar combined with chemotherapy from the first day, and CT perfusion imaging could be a reasonable method for evaluation of patient outcomes.

Loading Maanshan City Peoples Hospital collaborators
Loading Maanshan City Peoples Hospital collaborators